Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Learn More

Your Location is set to:

PROMINENT

Objective

The objective of the study is to find out if K-877 (also called pemafibrate), the study drug, compared to placebo (treatment which looks like the medicine but contains no active pemafibrate), lowers cardiovascular complications in adults with type-2 diabetes.  Those complications may be a heart attack or a stroke.

Principal Investigator(s)
Richard Zelman, MD

Clinical Trial Categories

  • Cardiovascular Disease with Diabetes
  • Cardiovascular Disease
  • Coronary Disease
Contact
Kelcie Brown, RN at
or kelciebrown@capecodhealth.org
How to Participate

Speak to your primary care physician/cardiologist or to our experienced research nurse:  Kelcie Brown, RN at 508-778-5900.

Location

  • Heart & Vascular Institute